World Journal of Pharmaceutical and Life Sciences
WJPLS
www.wjpls.org
SJIF Impact Factor: 6.129

DEVELOPMENT OF A PRAGMATIC APPROACH TO CORRECTING THE PRESENCE OF UNDEVELOPED DRUGS: A REVIEW

Ravi Shanker Vishwakarma*, Chandan Singh, Abhishek Pandey and Mohd. Washid Khan

Dept. of P.G. Studies and Research in Chemistry and Pharmacy R. D. University, Jabalpur M.P.

Corresponding Author: Ravi Shanker Vishwakarma
Dept. of P.G. Studies and Research in Chemistry and Pharmacy R. D. University, Jabalpur M.P.

Article Received on 21/03/2021 **Article Revised on 11/04/2021** **Article Accepted on 31/05/2021**

ABSTRACT

Oral drug delivery is the simplest form of drug administration; strict oral dosage forms are preferred for different form of dosage forms due to their slightness, good stability, precise volume, and quick to prepare. Hard measuring forms need to be well melted to lead to a good detection rate as long as they have a good detection. Solid dispersion systems were developed by formulating solid solutions through the dispersing molecules of active chemical compounds (APIs) into crystalline carriers instead of eutectic compounds. Solid dispersion consists of an active carrier or both polymeric and working carriers. It has been found that these types of programs can help greatly improve the availability of a well-soluble drug and at the same time help improve drug stability over the long term. More recently, more regulated release systems are using robust distribution technology to achieve a set free of water-soluble drugs with a shorter fraction of organic matter, representing the fourth generation of solid distribution.

KEYWORDS: Oral Route, bioavailability, active pharmaceutical ingredient, solid dispersions.

1. INTRODUCTION

Solid oral dosage forms need to be melted well to lead to a good consistency as long as they have a good consistency. Some recent estimates based on, about 40% of existing drugs do not dissolve well in water, and up to 60% of chemicals that come at first hand from synthesis experience the same problem.[1] Therefore, finding an effective way to increase the rate of elimination and dissolution of drugs is a major challenge for pharmacologists. Strong dispersion, is a useful method that can overcome the above mentioned limitations.[2] The first-generation carriers of solid distribution are carriers of crystals, such as urea and sugar. An excellent example of a strong first-generation dispersal is the eutectic mixture prepared by Sekiguchi and Obi,[2] the first solid dispersal prepared in the literature.[2] They are currently one of the most auspicious for improving the oral availability of water-soluble drugs. In case of Solid dispersion two components are consisting to produce solid dispersion routinely a hydrophilic carrier and a hydrophobic drug.[3] Amorphus or crystalline carrier with drug can be dispersed by molecules, amorphous particles (clusters), or crystalline particles. In solid dispersion drug particle size can reach a very small level as cells by rapid melting.[4] Drugs can be present in their amorphous forms which in theory represent the most powerful form of the substance, and therefore should be of great benefit to the apparent dissolution.[5] After almost 50 years of continuous research and development, a number of robust distribution methods have been developed. Depending on the bearing species, molecular structure and the addition of surfactants, the solid distribution has been divided into three generations.[6] Eutectic compounds usually consist of two crystalline substances and have a lower melting point than that of any other mixture of similar compounds. Later, other solid dispersion methods were developed by formulating solid solutions by molecular distribution of the active ingredient drug (API) in crystalline carriers (e.g., Mannitol) instead of eutectic compounds.[7,8] In these systems, a water-soluble drug is dispersed by molecules to dissolve carriers or volatile polymers that can prolong drug release from a strong dispersion system. The most widely used polymers in the distributed controlled release include ethyl cellulose, polyethylene oxide (PEO), HPC, Eudragit RS, RL, Kollicoat SR, Kollidon SR, HPMC, i -HPMCAS, and so on. The drug is usually removed from the system using augmentation and erosion methods.

As part of the biopharmaceutical classy program the drug has low melting and high availability and is a promising candidate for melting progress and availability through strong distribution.[9] Solid dispersion is defined as the dissolution of one or more active ingredients (hydrophobic) in an inert (hydrophilic) container in a

solid state prepared for dissolving, dissolving, or dissolving method. When solid dispersal is in contact with liquid coating, the empty substance is dissolved and the drug is released, the production area produces a higher distribution rate thus increasing the availability of an unresolved drug.[10] Factor in the morphological structure of drug dissolve. The amount of soluble chemicals has increased dramatically. Compared to prevalent dosage form such as tablets or capsules, solid dispensers can be used in a variety of ways that are more beneficial than the standard form above. In preparation for a strong distribution, a few factors should be considered; Carrier selection and physicochemical translation methods.[11] The use of novels and road companies will be of great help to architects to develop certain solid dispersion based formats used for marketing and clinical use. In the current review, current literature on new ways to prepare solid dispersion to increase solubility, solubility, therapeutic efficacy, and availability of water-soluble drugs is summarized and analyzed. In addition, the current state of solid dispersion, the patent status, and future prospects were also discussed.[12]

Table.1.1: Marketed products and their role using solid dispersion approach.

S.No	Product Name Indication Carrier system Company	Mechanism of Action	Carrier System	Company Name
01	Incivek (Telepravir)*	HCV	HPMCAS Vertex	Vertex Comp.
02	Intelence (Etravirine)*	HIV-Positive	HP-Methyl Cellulose	Tibotec/J&J
03	Isoptin SRE (Verapamil)	Hypertension	HPC/HPMC	Abbott Comp.
04	Kaletra (Lopinavir)*	HIV-Positive	Copovidone	Abbott Comp.
05	Kalydeco (Ivacaftor)	Cystic fibrosis	HPMCAS	Vertex Comp.
06	Norvir (Ritonavir)*	HIV-Positive	Copovidone	Abbott Comp.
07	Certican (Everolimus)*	Immunosuppressant	HP-Methyl Cellulose	Novartis Comp.
08	Fenoglide (Fenofibrate)*	High lipid level	PEG 6000	Santarus Comp.
09	Incivek (Telepravir)	HCV	HPMCAS	Vertex Comp.
10	188Gris- PEG(Griseofulvin)	Antimycoticum	PEG 400,8000	Pedinol Pharma

2. Process for Solid Dispersions

There are usually two main ways to prepare for solid dispersion: one to use the water phase as solvent and the melting method,[13] and the other by the solid phase as mechanical means, for example, milling.[14] It should be noted that the method used to prepare the amorphous solid dispersion can play an important role in physical stability in the systems and therefore the developers will need to consider which is the best amorphous system for the construction of a solid dispersion structure.



Fig. 1: Flow diagram represents the technique of solid dispersion.

(I) Melting Method

The soluble method is widely used to prepare for solid dispersion and some of the first dispersed drug application sites were prepared in this way. Normally, when dissolved, the drug and the carrier dissolve together and the high chemical conductivity of the material allows for the insertion of each other. Cooling often follows the solidification of melted mixtures and processes include the dissolution of ice bath, immersion in liquid nitrogen, with thin layer of stainless steel dispersed followed by cold preparation, spread on dry ice plates, and so on. Pulverization is often required to break the cake into smaller particles after cooling. However, there are some important barriers that can reduce the use of the melting method. First, degradation can occur in some drugs and carriers during heating at temperatures required for melting. Second, incomplete mismatch between the drug and carrier may be due to the high viscosity of certain carriers in the melted state. Therefore, other modified melting techniques, such as

hot melt extrusion, are designed to prevent these problems.[15] In this way, the carrier and the used drugs begin to be heated together at melting temperatures or at lower temperatures than for a limited period of time, followed by high-speed discharge. Finally, the resulting material is cooled to room temperature and processed.

(II) Solvent Method

Solvent process, the drug and the carrier are dissolved in the solvent (usually organic solvents) and the solvent is removed, and finally produce a solid dispersion. Solvent methods are very useful for thermo sensitive chemicals because solvent evaporation usually occurs at low temperatures. There are many types of solvent methods restricted by the solvent removal process, such as vacuum drying, hot plate heating, slow evaporation of solvent at low levels, rotating evaporator use, nitrogen use, spray suspension, ice drying, liquid use plural, and so on. Among these methods, spray drying method and ice drying method are probably the most widely used. In the spray drying process, the holder and the spray are simply dissolved or suspended and the solution is sprayed with an atomizer, providing very small droplets that can be easily dried using warm air flow. Limit on solvent methods is the use of various hydrocarbon solvents which increases the cost of formulation and leads to greater environmental risk.

(III) Ball Milling Method

The digestion of the ball differs from the soluble and soluble methods in that the solid distribution of the drug and the carrier are fixed in a solid state. This method has been widely used to create an amorphous class.[16] During digestion, powerful machines are developed that can help facilitate drug and carrier transport.[17] Heat may be produced in the region of the local collision between the balls and the wall of the pot, which may help to dissolve the tree into a carrier of misconduct. Studies have shown that solid solutions can be made using high-energy grinding techniques such as the ball-grinding planet. The advantages of grinding the ball to fix the solid dispersion include their thermosensitive counterpart efficiency and ease of handling, avoiding the use of bulk composites. However, compared to melting and melting techniques, ball grinding can be difficult to raise. Prolonged digestion can also lead to possible damage.

3. Molecular Structure of formless Solid Dispersions

There are currently two main types of formless solid dispersing cells: the standard model and the new model. Usually polymer carriers are more likely to form strong amorphous solutions, while low-weight carriers tend to form simple eutectic compounds or solid solutions.[18] In a typical model of solid amorphous dispersion, drug molecules are rarely trapped within a polymeric network in solid dispersed areas.[18] Molecular modeling is a special computer-based method used to mimic the functioning of molecules.[20] The distinguishing feature of this process is the defining of cellular systems at the atomic level. Molecular modeling techniques have great potential in studying the formation of solid dispersion at the cellular level. In this study, the formation of solid dispersion cells with a thermal dissolving mechanism was investigated by means of a quantitative measurement. Model results have shown that parallel polymer chains form random coils under temperature and drug molecules adhere to the surface of polymer coils.[19] These results suggest that the amorphous state of the drug molecule in a strong dispersion enhances its degradation properties.



(a) **(b)**

Fig.2 (a) the conventional model of amorphous solid solution and (b) a new model of amorphoussolid dispersions.

4. Physical Stability of Solid Dispersions

The physical stability of a strong dispersion depends largely on the condition of the dispersed drug. Here solid dispersion was given to two broad classes based on the body structure of the drug in the systems: crystalline drugs in solid dispersions and strong solvent dispersal (solid solution) in which the drugs are completely dispersed in a polymer series at the cellular level. Strong distribution containing crystalline drugs often has a low risk of instability, and in some cases instability is strongly associated with the body's instability of the carrier. Crystal-carrying substances, such as PEG and

lipids, often pose risks of instability in aging.[21] The discussion of how to assess the instability of these systems is discussed elsewhere, and here we focus more on the discussion of the stability of the amorphous solid dispersion. With a strong distribution of amorphous, although it has shown that it is very possible to improve the rate of dissolution of water-soluble drugs, such strong commercial use is severely limited. There are many barriers to marketing a strong distribution of amorphous, and in many cases the physical stability of dispersing is a major problem.[22,25]

5. Techniques for Solubility Enhancement

Solubility development strategies can be categorized by physical modification, chemical modification of a drug substance, and other techniques.

I. In case of Physical modification. It will reduce in particle size such as micronization and nanosuspension, drug dispersion in carriers such as eutectic compounds, solid dispersion, solid solutions and crystal modification modification such as polymorphs, amorphous form and cocrystallization,.
II. In case of Chemical Modification. Change of Ph, buffer utilization, complex derivatization, and salt formation.
III. In case of Mixed methods., The use of adjuvant such as surfactant, solubilizers, cosolvency, hydrotrophy, and excipients of the novel.

Future Prospects

Creating a new theoretical model and robust distribution methods will be the key to future success for solid dispersal construction. In this method are most widely used pharmaceutical distribution techniques that can improve solubility and the availability of water-soluble drugs. The main interests focus on lipid-based dispersion like nanocapsulation, solid dispersion and liquisolid dispersion (a drug dissolved in a soluble solvent and dispersed in solid solvents suitable for table or forcing), to cover the enhancement of applications and the preparation process, and the preparation process. of oral drugs. In addition, other strategies that can increase the spread of a tree such as climate reduction, crystalline bonding and incorporation compounds are discussed. The various distribution methods provide a productive platform to address the challenge of the formation of water-soluble drugs.

REFERENCES

1. Ke, P., Hasegawa, S., Al- Obaidi, H., Buckton G. Investigation of preparation methods on surface/bulk structural relaxation and glass fragility of amorphous solid dispersions. International Journal of Pharmaceutics, 2012; 422(1/2): 170–178.
2. Sekiguchi, K. and N. Obi, Studies on absorption of eutectic mixture. 1. A comparison of the behavior of eutectic mixture of sulfathiazole and that of ordinary sulfathiazole in man. Chemical and Pharmaceutical Bulletin, 1961. **9**(11): 866–872.
3. Chiou, W.L. and Riegelman. S., Pharmaceutical applications of solid dispersion systems. Journal of Pharmaceutical Sciences, 1971; 60(9): 1281–1302.
4. Vippagunta, S.R., Z. Wang, S. Hornung, et al., Factors affecting the formation of eutectic solid dis- persions and their dissolution behavior. Journal of Pharmaceutical Sciences, 2007; 96(2): 294–304.
5. Janssens, S. and G. Van den Mooter, Review: physical chemistry of solid dispersions. Journal of Pharmacy and Pharmacology, 2009; 61(12): 1571–1586.
6. Vasconcelos, T., B. Sarmento, and P. Costa, Solid dispersions as strategy to improve oral bio-availability of poor water soluble drugs. Drug Discovery Today, 2007; 12(23/24): 1068–1075.
7. Kanig, J.L., Properties of fused mannitol in compressed tablets. Journal of Pharmaceutical Sciences, 1964; 53: 188–192.
8. Chiou, W.L. and S. Riegelman, Preparation and dissolution characteristics of several fast- releasesolid dispersions of griseofulvin. Journal of Pharmaceutical Sciences, 1969; 58(12): 1505–1510.
9. R. Kurmi, D. K. Mishra, D.K. Jain, Solid dispersion: a novel means of solubility enhancement, J Crit Rev, 2016; 3(1): 1-8.
10. B. Kumar, Solid Dispersion- A Review; Pharma Tutor, 2017; 5(2): 24-29.
11. Beena Kumari, Harish Kumar Bishnoi. SOLID DISPERSION: ITS TYPES AND MECHANISM OF ENHANCEMENT OF SOLUBILITY BY SOLID DISPERSION. J Pharm Res., 2019; 8(3): 65-71.
12. Sultan A, Syed S.I, Afzal H ,Mohammad A. Altamimi,Nabil K. Alruwaili,Fahad Alotaibi,Abdullah Alanazi, Faiyaz Shakeel,Potential of solid dispersions to enhance solubility, bioavailability, and therapeutic efficacy of poorly water-soluble drugs: newer formulation techniques, current marketed scenario and patents,:Drug Delivery, 2020; 27(1): 1625-1643.
13. Serajuddin, A.T.M., Solid dispersion of poorly water- soluble drugs: early promises, subsequent problems, and recent breakthroughs. Journal of Pharmaceutical Sciences, 1999; 88(10): 1058–1066.
14. Patterson, J.E., M. B. James, A. H. Forster, et al., Preparation of glass solutions of three poorly water soluble drugs by spray drying, melt extrusion and ball milling. International Journal of Pharmaceutics, 2007; 336(1): 22–34.
15. Karanth, H., V.S. Shenoy, and R.R. Murthy, Industrially feasible alternative approaches in the manufacture of solid dispersions: a technical report. AAPS PharmSciTech, 2006; 7(4): 8.
16. Willart, J.F. and M. Descamps, Solid state amorphization of pharmaceuticals. Molecular Pharmaceutics, 2008; 5(6): 905–920.
17. Gupta, M.K., A. Vanwert, and R.H. Bogner, Formation of physically stable amorphous drugs by milling with neusilin. Journal of Pharmaceutical Sciences, 2003; 92(3): 536–551.
18. Leuner, C. and J. Dressman, Improving drug

solubility for oral delivery using solid dispersions. European Journal of Pharmaceutics and Biopharmaceutics, 2000; 50(1): 47–60.
19. Ouyang, D.,Investigating the molecular structures of solid dispersions by the simulated anneal- ing method. Chemical Physics Letters, 2012; 554: 177–184.
20. Leach, A.R., Molecular Modelling: Principles and Applications. 2nd edn. Prentice Hall, 2001.
21. Khan, N. and D.Q.M. Craig, Role of blooming in determining the storage stability of lipid- based dosage forms. Journal of Pharmaceutical Sciences, 2004; 93(12): 2962–2971.
22. Prentis, R.A., Y. Lis, and S.R. Walker, Pharmaceutical innovation by the seven UK- owned phar- maceutical companies (1964–1985). British Journal of Clinical Pharmacology, 1988; 25(3): 387–396.
23. Crowley, M.M., S.K. Battu, S.B. Upadhye, et al., Pharmaceutical applications of hot- melt extrusion: part I. Drug Development and Industrial Pharmacy, 2007; 33(9): 909–926.
24. Repka, M.A., Battu S.K., Upadhye S.B., et al., Pharmaceutical applications of hot- melt extru- sion: part II. Drug Development and Industrial Pharmacy, 2007; 33(10): 1043–1057.
25. Paudel, A., Worku Z.A., Meeus J., et al., Manufacturing of solid dispersions of poorly water soluble drugs by spray drying: formulation and process considerations. International Journal of Pharmaceutics, 2012; 453(1): 253–284.